89 annotations
Page 3 of 5
We're also investing in a wide range of late-stage Phase III programs.
(No comment added)
Transcript
2024 Q2
9 Aug 24
in June, we published results in the New England Journal from our Phase II trial of tirzepatide for metabolic dysfunction associated steatohepatitis, or MASH, with Stage II or III fibrosis
(No comment added)
Transcript
2024 Q2
9 Aug 24
We're engaged with regulatory authorities on a potential Phase III registration strategy, and we're also encouraged by the potential read-through of these results to retatrutide, which also showed significant improvements in liver fats in Phase II.
(No comment added)
Transcript
2024 Q2
9 Aug 24
more than half of the patients taking tirzepatide achieved improvement in fibrosis at 52 weeks
(No comment added)
Transcript
2024 Q2
9 Aug 24
In the first half of the year, we launched the quick pen presentation in the U.K., Germany and the UAE.
So far in Q3, we've also launched Mounjaro Quick Pen in Spain and plan to launch an additional markets throughout 2024.
(No comment added)
Transcript
2024 Q2
9 Aug 24
expect this facility will initiate production by the end of 2024 with product available to ship in 2025
(No comment added)
Transcript
2024 Q2
9 Aug 24
Since 2020, we have committed more than $18 billion to build, upgrade or acquire facilities in the U.S. and Europe
(No comment added)
Transcript
2024 Q2
9 Aug 24
In July, we announced a definitive agreement to acquire Morphic, a biopharma company developing oral -- therapies for treatment of serious chronic diseases, including a Phase II asset being evaluated in inflammatory bowel disease.
(No comment added)
Transcript
2024 Q2
9 Aug 24
We have now launched our multidose quick pen in multiple markets outside the U.S. with positive early indicators of patient adoption.
(No comment added)
Transcript
2024 Q2
9 Aug 24
In May, we announced plans to invest an additional $5.3 billion in our Lebanon, Indiana manufacturing sites, bringing our total investment there to $9 billion.
(No comment added)
Transcript
2024 Q2
9 Aug 24
We have initiated a broad Phase III development program studying the molecule in obesity, OSA, osteoarthritis, cardiovascular and renal outcomes as well as type 2 diabetes. These readouts start in 2026.
(No comment added)
Transcript
2024 Q2
9 Aug 24
Orforglipron, our oral GLP-1 small molecule, has a comprehensive Phase III program underway in diabetes and obesity with nine trials currently running and readout starting next year.
(No comment added)
Transcript
2024 Q2
9 Aug 24
We achieved several key pipeline milestones, including the approval of Kisunla, the brand name for donanemab in the U.S. for the treatment of Alzheimer's disease, the approval of Jaypirca in Japan for people with relapsed or refractory mantle cell lymphoma who are resistant or intolerant to other BTK inhibitors, the submission of tirzepatide in the U.S. and the EU for the treatment of moderate to severe obstructive sleep apnea in adults with obesity and the positive top line results from the SUMMIT Phase III trial evaluating tirzepatide in adults with heart failure with preserved injection fraction and obesity.
(No comment added)
Transcript
2024 Q2
9 Aug 24
the approval of the Kwikpen in Europe that just came in slightly ahead of our expectation gives us additional confidence in our ability to launch Kwikpen for patients in Europe
(No comment added)
Transcript
2024 Q1
24 May 24
we have six sites right now between the two sites in North Carolina, a site in [ Arland ] two sites in Indiana, a site in Germany and then the seventh one that we just purchased, they are all either ramping up or under construction
(No comment added)
Transcript
2024 Q1
24 May 24
Of course, there's arguments that can be heard about GIP agonism versus antagonism. We've placed our bets, and we like the data we got with GIP agonism. .
On [ Cagri sema ], of course, adding more agonism on different pathways on top of GLP-1 is a good idea. That's what we have with tirzepatide, as a dual agonist.
(No comment added)
Transcript
2024 Q1
5 May 24
tirzepatide could potentially be the first pharmacological treatment for the underlying disease
(No comment added)
Transcript
2024 Q1
5 May 24
approximately 70% of people with OSA also live with obesity
(No comment added)
Transcript
2024 Q1
5 May 24
OSA is a sleep-related breathing disorder
(No comment added)
Transcript
2024 Q1
5 May 24
OSA is a sleep-related breathing disorder
(No comment added)
Transcript
2024 Q1
5 May 24